abstract
- Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial. The aim of the Evidence-Based Medicine (EBM) Section is to bring the readership clinically relevant and practical evidence-based medicine principles and topic reviews. This EBM - Therapy review focuses on a relatively new therapy option for Emergency Department patients with acute myocardial infarction.